Monoclonal VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Research Question:
How well does a monoclonal antibody, "anti-SEMA4D monoclonal antibody VX15/2503,"
work in treating patients with stage I-III pancreatic cancer?
Basic Study Information
Purpose:
This randomized phase I trial studies how well a monoclonal antibody, anti-SEMA4D
monoclonal antibody VX15/2503, works in treating patients with stage I-III pancreatic
cancer. It will be used with or without another monoclonal antibody, ipilimumab or
nivolumab. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503,
ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and
spread.
Location: University of Rochester Medical Center
Study Reference #: SGIM19105
Lead Researcher (Principal Investigator)
Lead Researcher:
David Linehan
Study Contact Information
Study Coordinator: Chris LeFeber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search